OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

McCaskill Reacts to Mylan Announcement on Move to Increase EpiPen Rebates

Statement

Date: Aug. 25, 2016
Location: Washington, DC
Issues: Business and Consumers Health and Health Care

U.S. Senator Claire McCaskill issued the following statement today, after reports that Mylan would provide rebates to consumers in an attempt to lower out-of-pocket costs on the severe allergy treatment drug EpiPen:

"I'm tired of playing whack-a-mole with these pharmaceutical companies that are grabbing obscene profits while they have a monopoly. Rebates help, but ultimately these price increases are showing a market failure that Americans are paying for. And we can't afford it."

Yesterday, McCaskill and Maine Republican Susan Collins, who together lead the Senate Aging Committee, sent a letter to Heather Bresch, the CEO of Mylan, to request answers and information about the company's drastic price increase of EpiPen by 480% since 2008. The Senators also requested any analysis used by Mylan relating to the pricing or market share of EpiPen since 2007, along with any information reviewed or generated by Mylan's Board of Directors relating to the drug over the same period.

McCaskill, through her work on the Aging Committee, has previously investigated dramatic increases in pharmaceutical drug prices, holding a series of hearings earlier this year on the issue.


Source
arrow_upward